This is an Phase Ib/2 study, single arm, single cohort study to determine the safety and
tolerability of Dupilumab with PD-(L)1 blockade for patients with relapsed/refractory
metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1
blocking agents in patients with relapsed/refractory NSCLC, who have progressed on prior
PD-(L)1 agents